Oxaliplatin enhances TRAIL‐induced apoptosis in gastric cancer cells by CBL‐regulated death receptor redistribution in lipid rafts

[1]  J. Saurin,et al.  p53-Mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells , 2008, Oncogene.

[2]  A. Johnson,et al.  Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells. , 2008, Gynecologic oncology.

[3]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[4]  Yu Zeng,et al.  Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)‐receptor (R) 2‐mediated apoptosis by inducing TRAIL‐R2 expression , 2007, Cancer science.

[5]  L. Andĕra,et al.  Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts , 2007, Molecular Cancer Therapeutics.

[6]  Faustino Mollinedo,et al.  Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. , 2007, Blood.

[7]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Wilson,et al.  Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP , 2005, Molecular Cancer Therapeutics.

[9]  K. Sada,et al.  Selective Inhibition of FcεRI-Mediated Mast Cell Activation by a Truncated Variant of Cbl-b Related to the Rat Model of Type 1 Diabetes Mellitus , 2005 .

[10]  T. Hickish,et al.  Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF , 2005, British Journal of Cancer.

[11]  H. Hollema,et al.  Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. , 2005, European journal of cancer.

[12]  E. Solary,et al.  Cisplatin-Induced CD95 Redistribution into Membrane Lipid Rafts of HT29 Human Colon Cancer Cells , 2004, Cancer Research.

[13]  K. Sada,et al.  Negative regulation of FcϵRI-mediated mast cell activation by a ubiquitin-protein ligase Cbl-b , 2004 .

[14]  D. Seol,et al.  Upregulation of FLIPS by Akt, a possible inhibition mechanism of TRAIL‐induced apoptosis in human gastric cancers , 2003, Cancer science.

[15]  H. Safran,et al.  Status of treatment for advanced gastric carcinoma , 2003, Current oncology reports.

[16]  T. Asano,et al.  Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. , 2003, Cancer research.

[17]  J. Lord,et al.  The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. , 2002, Biochemical and biophysical research communications.

[18]  M. Kaminishi,et al.  Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. , 2002, International journal of oncology.

[19]  R. Geahlen,et al.  The Lck SH3 Domain Negatively Regulates Localization to Lipid Rafts through an Interaction with c-Cbl* , 2002, The Journal of Biological Chemistry.

[20]  Hai-Tao He,et al.  An essential role for membrane rafts in the initiation of Fas/CD95‐triggered cell death in mouse thymocytes , 2002, EMBO reports.

[21]  F. Alt,et al.  Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. , 2000, Immunity.

[22]  H. Friess,et al.  The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract , 1999, Oncogene.

[23]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[24]  D. Cunningham,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2010, The New England journal of medicine.